1. Mutually exclusive mutation profiles define functionally related genes in muscle invasive bladder cancer.
- Author
-
Sangster AG, Gooding RJ, Garven A, Ghaedi H, Berman DM, and Davey SK
- Subjects
- Biomarkers, Tumor genetics, Cell Cycle, Databases, Genetic, Epistasis, Genetic, Gene Regulatory Networks, Humans, DNA-Binding Proteins genetics, Histone Demethylases genetics, Mutation, Neoplasm Proteins genetics, Retinoblastoma Binding Proteins genetics, Ubiquitin-Protein Ligases genetics, Urinary Bladder Neoplasms genetics
- Abstract
Muscle Invasive bladder cancer is known to have an abundance of mutations, particularly in DNA damage response and chromatin modification genes. The role of these mutations in the development and progression of the disease is not well understood. However, a mutually exclusive mutation pattern between gene pairs could suggest gene mutations of significance. For example, a mutually exclusive mutation pattern could suggest an epistatic relationship where the outcome of a mutation in one gene would have the same outcome as a mutation in a different gene. The significance of a mutually exclusive relationship was determined by establishing a normal distribution of the conditional probabilities for having a mutation in one gene and not the other as well as the reverse relationship for each gene pairing. Then these distributions were used to determine the sigma-magnitude of standard deviation by which the observed value differed from the expected, a value that can also be interpreted as the 'p-value'. This approach led to the identification of mutually exclusive mutation patterns in KDM6A and KMT2D as well as KDM6A and RB1 that suggested the observed mutation pattern did not happen by chance. Upon further investigation of these genes and their interactions, a potential similar outcome was identified that supports the concept of epistasis. Knowledge of these mutational interactions provides a better understanding of the mechanisms underlying muscle invasive bladder cancer development, and may direct therapeutic development exploiting genotoxic chemotherapy and synthetic lethality in these pathways., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2022
- Full Text
- View/download PDF